search
Back to results

The Arterial Measurement of the Blood Flow Volume After Iloprost Stimulation (ILOFLOW)

Primary Purpose

Diabetes, Arteriosclerosis, Peripheral Arterial Occlusive Disease

Status
Unknown status
Phase
Phase 2
Locations
Austria
Study Type
Interventional
Intervention
Ilomedin
Sponsored by
Prim PD Dr Afshin Assadian
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes focused on measuring blood flow volume, ilomedin, measurement, intraarterial, neuropathy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • patients with diabetes and non diabetes
  • patients with peripheral artery occlusive disease and who undergo surgical treatment in distal vessels
  • spinal anesthesia
  • written consent

Exclusion Criteria:

  • pregnancy
  • heart attack the last 6 months
  • stroke the last 6 months
  • hypotension
  • edema of the lungs
  • heart failure
  • heart disease
  • chronic obstructive pulmonary disease (COPD)
  • ulcus ventriculi
  • renal disease
  • coronary disease
  • immaturity
  • general anesthesia

Sites / Locations

  • Department of vascular and endovascular surgery, Georg Hagmüller Institute for Vascular Research WilhelminenhospitalRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Ilomedin, bloodflow volume, measurement,

Arm Description

Surgery was performed under general anesthesia via a longitudinal skin incision. After systemic administration of 5000 IU of unfractionated Heparin, the peripheral vessels were clamped. Following a longitudinal arteriotomy, thrombendarterectomy of the common femoral artery was performed in all cases, extending into the deep femoral artery and superficial femoral artery when necessary. At the end of the reconstruction, 3000 ng of iloprost (Ilomedin), diluted in 15ml saline solution, were administered into the common femoral artery. Distal to the injection site doppler flow measurement was performed at the common femoral artery prior to arteriotomy, prior to the intraarterial application of iloprost and 5 and 10 minutes afterwards, using the Sono TT FlowLab instrument. During the procedure, systemic arterial blood pressure was continuously documented using a pressure transducer connected to an intraarterial cannula placed in the radial artery of the forearm.

Outcomes

Primary Outcome Measures

The measurement of the blood flow volume is done with the Sono TT FlowLab (em-Tec GmbH, Munich) ultrasound instrument on the common femoral artery in diabetics and non-diabetics after ilomedin administration.
Before surgery reconstruction the first measurement with the Sono TT FlowLab (em-Tec GmbH, Munich) ultrasound instrument will be done on the common femoral artery and then after surgery reconstruction. Therefore there will be different measuring heads exactly fitting around the vessels. Then the administration of 3000ng Ilomedin® in 15ml saline will be injected into the common femoral artery via a a cannula over two minutes if the systolic blood pressure of the patient is over 100mm Hg. The blood flow volume will be measured again after five and ten minutes on the same point. Those results will be documented.

Secondary Outcome Measures

Full Information

First Posted
January 7, 2013
Last Updated
October 16, 2018
Sponsor
Prim PD Dr Afshin Assadian
Collaborators
Wilhelminenspital Vienna
search

1. Study Identification

Unique Protocol Identification Number
NCT01774058
Brief Title
The Arterial Measurement of the Blood Flow Volume After Iloprost Stimulation
Acronym
ILOFLOW
Official Title
The Intraoperative Arterial Measurement of the Blood Flow Volume After Iloprost Stimulation in Diabetics and Non-diabetics: Implication for Outcome-prediction and Perioperative Therapy
Study Type
Interventional

2. Study Status

Record Verification Date
October 2018
Overall Recruitment Status
Unknown status
Study Start Date
October 2012 (undefined)
Primary Completion Date
June 2019 (Anticipated)
Study Completion Date
June 2019 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Prim PD Dr Afshin Assadian
Collaborators
Wilhelminenspital Vienna

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
A prospective case-control study was performed to investigate the effect of iloprost on the intraoperative flow volume in diabetic and non-diabetic patients as well as the effect of peripheral neuropathy in patients with peripheral arterial occlusive disease (PAOD) undergoing arterial reconstruction (primary endpoint). 100 patients undergoing femoral artery reconstruction or femorodistal bypass surgery were included. Prior to surgery, peripheral nerve conduction velocity was measured. Blood flow volume at the common femoral artery was assessed using a Doppler flowmeter (Sono TT FlowLab; ) before reconstruction, prior to the intraarterial application of 3000ng of iloprost and 5 and 10 minutes afterwards. Peripheral resistance units (PRU) were calculated as a function of mean systemic arterial pressure (MAP) and flow volume (VF): PRU = MAP (mmHg) / VF (ml/min).
Detailed Description
The therapeutic properties of prostanoids appear to be primarily due to its vasodilative effect. However, the inhibition of platelet aggregation with a limitation of thrombus formation and the inhibition of the adhesion of leucocytes to endothelial lesions also help to improve blood flow in the peripheral circulation . It is currently unclear which effects of prostanoids are predominant for diabetic patients. The present study was performed to assess potential differences of iloprost efficiency for patients with or without type II diabetes mellitus with or without peripheral neuropathy. The study was a single center, controlled, non- randomized interventional study. All patients provided their written consent. The study has been approved by the Ethics Committee of the city of Vienna in 2012 (EC nr: 11-144-0512) and was extended annually for the last two years. Performance of the study complied with the World Medical Association Declaration of Helsinki regarding ethical conduct of research involving human subjects. The study was designed to enroll 100 consecutive patients with peripheral arterial occlusive disease undergoing surgical reconstruction of the inguinal arteries and/or femorodistal bypass surgery. Indication for surgery included PAOD Fontaine stage IIb (waking distance less than 200 meters), III (rest pain) or IV (tissue loss). Surgical procedures were planned and the absence of inflow stenoses verified based on MRI or CT angiography. Exclusion criteria for participation in the study comprised contraindications for the application of iloprost as well as a planned spinal anesthesia. Patients were divided into two groups based on being diabetic type II or non-diabetic. Before surgery measurement of nerve conduction velocity was performed by a trained nurse at the Department of Physiotherapy in order to determine the presence of neuropathy. Surgery was performed under general anesthesia via a longitudinal skin incision. After systemic administration of 5000 IU of unfractionated Heparin, the peripheral vessels were clamped. After longitudinal arteriotomy, thrombendarterectomy of the common femoral artery was performed in all cases, extending into the deep femoral artery and superficial femoral artery when necessary. In some cases, this was followed by femoropopliteal bypass surgery. Provided the systolic blood pressure was equal to or above 100 mmHg at the end of the reconstruction, 3000 ng of iloprost (Ilomedin), diluted in 15ml saline solution, were injected into the common femoral artery. Distal to the injection site doppler flow measurement was performed at the common femoral artery prior to arteriotomy, prior to the intraarterial application of iloprost, 5 and 10 minutes afterwards, using the Sono TT FlowLab instrument (em-Tec GmbH, Munich). Transmission heads were selected to fit tightly around the reconstructed vessel without producing a stenosis. During the procedure, systemic arterial blood pressure was continuously documented using a pressure transducer connected to an intraarterial cannula placed in the radial artery of the forearm. The result of the arterial reconstruction was routinely checked by intraoperative on- table angiography. Before discharge from the hospital the surgical reconstruction was controlled by duplex ultrasound as well as an assessment of the ankle brachial index. Statistical analysis was performed with SPSS 15.0 for Windows (SPSS Inc, Chicago, Ill). To correct all measurements of flow volume for blood pressure, peripheral resistance units (PRU) were calculated as a function of mean systemic arterial pressure (MAP) and flow volume (VF): PRU = MAP (mmHg) / VF (ml/min). The patient population was stratified by the presence of diabetes and by the presence of peripheral neuropathy in the operated limb. Kolmogorov-Smirnov testing confirmed normal distribution of all continuous variables. Descriptive statistics (mean, standard deviation, range) were applied to acquired data, and tests for dependent or independent variables were used for comparison of continuous variables, as applicable. Categorical variables were expressed as frequencies and percentages, and differences between groups were investigated by the Pearson Chi -square and Fisher exact tests. Patient characteristics potentially modulating the effect of iloprost were investigated by linear regression analysis. P values < 0.05 were considered significant.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes, Arteriosclerosis, Peripheral Arterial Occlusive Disease, Neuropathy
Keywords
blood flow volume, ilomedin, measurement, intraarterial, neuropathy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Ilomedin, bloodflow volume, measurement,
Arm Type
Experimental
Arm Description
Surgery was performed under general anesthesia via a longitudinal skin incision. After systemic administration of 5000 IU of unfractionated Heparin, the peripheral vessels were clamped. Following a longitudinal arteriotomy, thrombendarterectomy of the common femoral artery was performed in all cases, extending into the deep femoral artery and superficial femoral artery when necessary. At the end of the reconstruction, 3000 ng of iloprost (Ilomedin), diluted in 15ml saline solution, were administered into the common femoral artery. Distal to the injection site doppler flow measurement was performed at the common femoral artery prior to arteriotomy, prior to the intraarterial application of iloprost and 5 and 10 minutes afterwards, using the Sono TT FlowLab instrument. During the procedure, systemic arterial blood pressure was continuously documented using a pressure transducer connected to an intraarterial cannula placed in the radial artery of the forearm.
Intervention Type
Drug
Intervention Name(s)
Ilomedin
Other Intervention Name(s)
Product Code 1-22460, ATC Code: B01AC11, concentrate and solvent for injection
Intervention Description
3000ng ilomedin in 15ml salt water will be injected intraarterial into the common femoral artery over 2 minutes for one time,then the investigators will measure the blood flow volume after 5 and then after 10 minutes on the common femoral artery. The patients will be observed by the anaesthesiologist. The patient will get ilomedin one day before the surgery and then for 6 day after surgery into the vein. (10microgramm/o,5ml in 250ml salt water)
Primary Outcome Measure Information:
Title
The measurement of the blood flow volume is done with the Sono TT FlowLab (em-Tec GmbH, Munich) ultrasound instrument on the common femoral artery in diabetics and non-diabetics after ilomedin administration.
Description
Before surgery reconstruction the first measurement with the Sono TT FlowLab (em-Tec GmbH, Munich) ultrasound instrument will be done on the common femoral artery and then after surgery reconstruction. Therefore there will be different measuring heads exactly fitting around the vessels. Then the administration of 3000ng Ilomedin® in 15ml saline will be injected into the common femoral artery via a a cannula over two minutes if the systolic blood pressure of the patient is over 100mm Hg. The blood flow volume will be measured again after five and ten minutes on the same point. Those results will be documented.
Time Frame
6 weeks after surgery

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: patients with diabetes and non diabetes patients with peripheral artery occlusive disease and who undergo surgical treatment in distal vessels spinal anesthesia written consent Exclusion Criteria: pregnancy heart attack the last 6 months stroke the last 6 months hypotension edema of the lungs heart failure heart disease chronic obstructive pulmonary disease (COPD) ulcus ventriculi renal disease coronary disease immaturity general anesthesia
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Afshin Assadian, Prim. PD Dr.
Phone
+34(0)1491504101
Email
afshin.assadian@wienkav.at
First Name & Middle Initial & Last Name or Official Title & Degree
Kornelia Hirsch, Dr.
Phone
+34(0)1491504101
Email
kornelia.hirsch@wienkav.at
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Afshin Assadian, Prim PD Dr
Organizational Affiliation
Georg Hagmüller Institute for Vascular Research Wilhelminenhospital Vienna, Austria
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of vascular and endovascular surgery, Georg Hagmüller Institute for Vascular Research Wilhelminenhospital
City
Vienna
ZIP/Postal Code
1160
Country
Austria
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Afshin Assadian, Prim PD Dr
Phone
+34(0)1491504101
Email
afshin.assadian@wienkav.at
First Name & Middle Initial & Last Name & Degree
Kornelia Hirsch, Dr
Phone
+34(0)1491504101
Email
kornelia.hirsch@wienkav.at
First Name & Middle Initial & Last Name & Degree
Afshin Assadian, Prim. PD.Dr

12. IPD Sharing Statement

Learn more about this trial

The Arterial Measurement of the Blood Flow Volume After Iloprost Stimulation

We'll reach out to this number within 24 hrs